Cite
Phenylthiocarbamide (PTC) perception in ultra-high risk for psychosis participants who develop schizophrenia: Testing the evidence for an endophenotypic marker
MLA
Brewer, Warrick J., et al. “Phenylthiocarbamide (PTC) Perception in Ultra-High Risk for Psychosis Participants Who Develop Schizophrenia: Testing the Evidence for an Endophenotypic Marker.” Psychiatry Research, vol. 199, no. 1, Aug. 2012, pp. 8–11. EBSCOhost, https://doi.org/10.1016/j.psychres.2012.03.010.
APA
Brewer, W. J., Lin, A., Moberg, P. J., Smutzer, G., Nelson, B., Yung, A. R., Pantelis, C., McGorry, P. D., Turetsky, B. I., & Wood, S. J. (2012). Phenylthiocarbamide (PTC) perception in ultra-high risk for psychosis participants who develop schizophrenia: Testing the evidence for an endophenotypic marker. Psychiatry Research, 199(1), 8–11. https://doi.org/10.1016/j.psychres.2012.03.010
Chicago
Brewer, Warrick J., Ashleigh Lin, Paul J. Moberg, Gregory Smutzer, Barnaby Nelson, Alison R. Yung, Christos Pantelis, Patrick D. McGorry, Bruce I. Turetsky, and Stephen J. Wood. 2012. “Phenylthiocarbamide (PTC) Perception in Ultra-High Risk for Psychosis Participants Who Develop Schizophrenia: Testing the Evidence for an Endophenotypic Marker.” Psychiatry Research 199 (1): 8–11. doi:10.1016/j.psychres.2012.03.010.